Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
12.08. | Sartorius to invest $3m for minority share in biotech start-up Nanotein | ||
12.08. | Fosun and Expedition make $645m licensing deal for respiratory drug | ||
11.08. | Lilly first to opt for confidential reimbursement price in Germany | ||
11.08. | Uncertainty around tariffs is a disincentive for pharma onshoring in the US | ||
11.08. | GSK's oral antibiotic for gonorrhoea set for FDA review | ||
11.08. | Japan MHLW approves Biostar's angel stem cell therapy for autism | ||
11.08. | Boehringer's Hernexeos receives fast-tracked FDA approval | ||
11.08. | FDA gives Arvinas and Pfizer's vepdegestrant NDA for breast cancer | ||
08.08. | Podcast: ePRO explained | ||
08.08. | EpiPen patent expiry opens new era for innovation | ||
08.08. | Gilead's Yeztugo sales "ahead of expectations" following launch | ||
08.08. | Uncertainty looms over FDA scheme to boost US manufacturing | ||
08.08. | Epkinly breaks ground in Phase III FL trial | ||
08.08. | FDA removes Ixchiq partial pause but tightens vaccine's use | ||
08.08. | MAXONA Pharma seeks FDA approval for pain relief MAX-001 | ||
08.08. | Podcast: Why the healthcare industry needs linked data | ||
08.08. | CorMedix signs agreement to acquire Melinta for $300m | ||
07.08. | Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly | ||
07.08. | Why Liverpool's Wirtz is causing concern at big pharma company Bayer | ||
07.08. | RFK Jr's mRNA funding halt signals "shift in US public health" | ||
07.08. | Astria Therapeutics licenses navenibart rights to Kaken for HAE | ||
07.08. | Top seven considerations when selecting primary packaging for injectable drugs | ||
07.08. | FDA gives accelerated approval to Jazz Pharma's diffuse midline glioma therapy | ||
06.08. | Teva's Ajovy becomes first migraine prevention drug approved for children | ||
06.08. | Novo Nordisk's diabetes and weight loss drug sales growth decelerates |